Functional high level expression of cytochrome P450 CYP2D6 using baculoviral expression systems

被引:34
作者
Paine, MJI
Gilham, D
Roberts, GCK
Wolf, CR
机构
[1] UNIV DUNDEE,NINEWELLS HOSP & MED SCH,BIOMED RES CTR,DUNDEE DD1 9SY,SCOTLAND
[2] UNIV LEICESTER,BIOL NMR CTR,LEICESTER LE1 9HN,LEICS,ENGLAND
基金
英国医学研究理事会;
关键词
CYP2D6; NADPH-cytochrome P450 reductase; baculovirus expression; coexpression; drug metabolism;
D O I
10.1006/abbi.1996.0154
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytochrome P-450 CYP2D6 plays a central role in the metabolism of many widely used therapeutic drugs including beta-adrenergic antagonists, antiarrhythmics, and tricyclic antidepressants. Recombinant baculoviruses have been constructed containing the full-length human CYP2D6 cDNA and used to express CYP2D6 in Spodoptera frugiperda (Sf9) cells. High levels of recombinant protein have been produced using either polyhedrin or basic protein promoters (0.05-0.20 nmol/mg cell protein; 0.05-0.15 nmol/liter). The enzyme is catalytically active toward CYP2D6 substrates such as bufuralol and metoprolol. In order to optimize catalytic activity human reductase was coexpressed with CYP2D6 in Sf9 cells; reductase activity was in the region of 1000-1500 units per mg cell protein, while spectrally active CY2D6 was in the range 10-20 pmol/mg cell protein. The K-m and K-cat values for bufuralol metabolism were estimated as 4.7 mu M and 12.23 min(-1), respectively. The use of the conventional very late promoters such as the polyhedrin promoter generate a large proportion of inactive CYP2D6. The problem was to a degree circumvented using the ''late'' basic promoter which is active earlier in the baculovirus infection cycle. The yield of functional CYP2D6 was at least as high as with very late promoters, but the proportion of inactive protein was reduced, Bufuralol hydroxylase activity could be measured directly by HPLC analysis of cell culture media supplemented with bufuralol, and we have developed a plate assay system which provides a simple method for the analysis of drug metabolism reactions using Sf9 cells. Expression using baculovirus provides a valuable source of functional CYP2D6 for work aimed at elucidating the structure and function of the enzyme. (C) 1996 Academic Press, Inc.
引用
收藏
页码:143 / 150
页数:8
相关论文
共 42 条
  • [1] NOVEL EXOGENOUS HEME-DEPENDENT EXPRESSION OF MAMMALIAN CYTOCHROME-P450 USING BACULOVIRUS
    ASSEFFA, A
    SMITH, SJ
    NAGATA, K
    GILLETTE, J
    GELBOIN, HV
    GONZALEZ, FJ
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1989, 274 (02) : 481 - 490
  • [2] METABOLIC OXIDATION PHENOTYPES AS MARKERS FOR SUSCEPTIBILITY TO LUNG-CANCER
    AYESH, R
    IDLE, JR
    RITCHIE, JC
    CROTHERS, MJ
    HETZEL, MR
    [J]. NATURE, 1984, 312 (5990) : 169 - 170
  • [3] BABREAU A, 1987, LANCET, V2, P1213
  • [4] EXPRESSION AND ENZYMATIC-ACTIVITY OF RECOMBINANT CYTOCHROME-P450 17-ALPHA-HYDROXYLASE IN ESCHERICHIA-COLI
    BARNES, HJ
    ARLOTTO, MP
    WATERMAN, MR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (13) : 5597 - 5601
  • [5] BACULOVIRUS EXPRESSION OF BOVINE CYTOCHROME P450C17 IN SF9 CELLS AND COMPARISON WITH EXPRESSION IN YEAST, MAMMALIAN-CELLS, AND ESCHERICHIA-COLI
    BARNES, HJ
    JENKINS, CM
    WATERMAN, MR
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 315 (02) : 489 - 494
  • [6] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [7] BUTERS JTM, 1994, DRUG METAB DISPOS, V22, P688
  • [8] STRUCTURE OF CYTOCHROME P450ERYF INVOLVED IN ERYTHROMYCIN BIOSYNTHESIS
    CUPPVICKERY, JR
    POULOS, TL
    [J]. NATURE STRUCTURAL BIOLOGY, 1995, 2 (02): : 144 - 153
  • [9] THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS
    EICHELBAUM, M
    GROSS, AS
    [J]. PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) : 377 - 394
  • [10] CATALYTIC ACTIVITIES OF HUMAN DEBRISOQUINE 4-HYDROXYLASE CYTOCHROME-P450 (CYP2D6) EXPRESSED IN YEAST
    ELLIS, SW
    CHING, MS
    WATSON, PF
    HENDERSON, CJ
    SIMULA, AP
    LENNARD, MS
    TUCKER, GT
    WOODS, HF
    [J]. BIOCHEMICAL PHARMACOLOGY, 1992, 44 (04) : 617 - 620